KRAS G12D Peptide (VVVGADGVGK) – Catalog #B2026700

KRAS G12D Peptide (VVVGADGVGK; Catalog #B2026700) is a synthetic, lyophilized 10-amino acid peptide fragment corresponding to a region of the KRAS (Kirsten rat sarcoma viral oncogene homolog) protein that contains the G12D point mutation. With a molecular weight of 900.04 Da and supplied as 1 mg, it serves as an immunogen, capture reagent, or diagnostic control in research focused on KRAS-driven malignancies.

Scientific Overview

KRAS is a small GTPase that acts as a molecular switch controlling cell proliferation, differentiation, and survival. The G12D mutation at codon 12 is one of the most common oncogenic KRAS alterations, accounting for roughly 10–20% of all KRAS mutations in human cancers. This single nucleotide substitution (GGT to GAT) results in replacement of glycine with aspartate at position 12, blocking the intrinsic GTPase activity of KRAS and keeping it locked in the active, GTP-bound state. Consequently, KRAS G12D acts as a dominant oncogene, driving uncontrolled signaling and proliferation in pancreatic, lung, colorectal, and other solid tumors.

Key applications include:

• Immunogen for raising antibodies and monoclonal antibodies specific to KRAS G12D
• Positive control in ELISA, immunoassay, and diagnostic assay development
• Antigen substrate in KRAS mutation detection and screening assays
• Research into KRAS-driven immune evasion and drug resistance

Usage & Handling Guidance

Store the lyophilized powder at −20°C in a tightly sealed container. Upon receipt, briefly centrifuge the vial before opening to collect any powder from the cap and walls. To reconstitute, add appropriate buffer (e.g., PBS or TBS) to the desired concentration. Mix gently and allow the powder to dissolve fully; brief sonication in a water bath may aid dissolution. Prepare single-use aliquots and store at −20°C; repeated freeze–thaw cycles may reduce peptide integrity.

• Reconstitution: Dissolve in sterile buffer appropriate for your assay (e.g., carbonate-bicarbonate buffer for antibody coupling).
• Immunization: Consult established immunization protocols; peptide conjugation to a carrier protein (e.g., KLH) may improve immunogenicity.
• Assay use: Optimize peptide concentration empirically for your assay platform.

What You Get

• 1 mg of synthetic KRAS G12D peptide (VVVGADGVGK), lyophilized
• Defined, reproducible sequence for immunological and diagnostic applications
• A toolbox for capturing and detecting KRAS G12D mutations
• For research use only (RUO)

Why Researchers Choose It

• Specific to the clinically important KRAS G12D hotspot mutation
• Smaller than full-length KRAS, making it convenient for coupling and immunization
• Homogeneous, synthetic peptide with batch-to-batch consistency
• Useful for validating assay performance and detecting KRAS mutations in clinical research

Frequently Asked Questions (FAQ)

• Why use this peptide instead of full-length KRAS protein?
  Peptides are smaller, easier to handle, more stable, and more cost-effective. They can be coupled directly to carriers or support materials for immunization or assay format.
• What carrier should I use for immunization?
  Common carriers include KLH (keyhole limpet hemocyanin) and BSA (bovine serum albumin). Consult published immunization protocols and request technical advice if needed.
• How should I store the reconstituted peptide?
  At −20°C in sterile, sealed tubes. Use fresh aliquots to avoid freeze–thaw degradation.
• Can this peptide detect KRAS mutations in samples?
  This peptide is an antigen or immunogen. To detect mutations, you would develop antibodies or other binding reagents against this peptide or use it as a capture reagent in an assay format.
• Can I get a COA or analytical data?
  Request a quote or contact us and we will provide available lot documentation.

References

• Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, Xu H, Cao Z, Feng X, Xue Q, Wang Y, Sun N, He J. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun (Lond). 2022;42(9):828-847.
• Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022;28(10):2171-2182.
• Zhou C, Li C, Luo L, Li X, Jia K, He N, Mao S, Wang W, Shao C, Liu X, Huang K, Yu Y, Cai X, Chen Y, Dai Z, Li W, Yu J, Li J, Shen F, Wang Z, He F, Sun X, Mao R, Shi W, Zhang J, Jiang T, Zhang Z, Li F, Ren S. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024;42(7):1286-1300.e8.
• Stickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer. Oncol Res. 2024;32(5):799-805.